264 related articles for article (PubMed ID: 27875356)
1. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Shukla T; Singh S; Tandon P; McCurdy JD
J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
[TBL] [Abstract][Full Text] [Related]
2. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
3. Risk of infections associated with biological treatment in inflammatory bowel disease.
Andersen NN; Jess T
World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.
Hradsky O; Copova I; Zarubova K; Durilova M; Nevoral J; Maminak M; Hubacek P; Bronsky J
Dig Dis Sci; 2015 Nov; 60(11):3399-407. PubMed ID: 26091801
[TBL] [Abstract][Full Text] [Related]
5. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
6. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
7. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.
Ma C; Walters B; Fedorak RN
World J Gastroenterol; 2013 Jun; 19(21):3347-51. PubMed ID: 23745038
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence.
Hissong E; Chen Z; Yantiss RK
Mod Pathol; 2019 Jul; 32(8):1210-1216. PubMed ID: 30952971
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.
Wisniewski A; Kirchgesner J; Seksik P; Landman C; Bourrier A; Nion-Larmurier I; Marteau P; Cosnes J; Sokol H; Beaugerie L;
United European Gastroenterol J; 2020 Apr; 8(3):303-313. PubMed ID: 32529821
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy.
Pillet S; Pozzetto B; Roblin X
World J Gastroenterol; 2016 Feb; 22(6):2030-45. PubMed ID: 26877608
[TBL] [Abstract][Full Text] [Related]
14. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
15. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
16. Risk of infections with biological agents.
Kopylov U; Afif W
Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
[TBL] [Abstract][Full Text] [Related]
17. Complications of biologics in inflammatory bowel disease.
Sousa P; Allez M
Curr Opin Gastroenterol; 2015 Jul; 31(4):296-302. PubMed ID: 26039721
[TBL] [Abstract][Full Text] [Related]
18. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.
Abreu C; Rocha-Pereira N; Sarmento A; Magro F
World J Gastroenterol; 2015 Jun; 21(21):6491-8. PubMed ID: 26074688
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience.
Bontà J; Zeitz J; Frei P; Biedermann L; Sulz MC; Vavricka SR; Scharl S; Fried M; Rogler G; Scharl M
Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1329-34. PubMed ID: 27482785
[TBL] [Abstract][Full Text] [Related]
20. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
